Sam­sung Bio and Bax­ter di­al up man­u­fac­tur­ing deal to $223M

Bax­ter Health­care will pay Sam­sung Bi­o­log­ics an ex­tra $208 mil­lion to man­u­fac­ture cer­tain drug prod­ucts un­til the end of 2034 in a re­vised man­u­fac­tur­ing con­tract …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.